Quarterly report · Q2
4583.TEDINET S100S9VE
Period2023-01-01 → 2023-06-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Amends S100RN56.
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥359m | 2023-01-01 → 2023-06-30 | Standalone | Net sales |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥278m | 2022-01-01 → 2022-06-30 | Standalone | Net sales |
| Operating income | −¥659m | 2023-01-01 → 2023-06-30 | Standalone | Operating income |
| Operating income | −¥779m | 2022-01-01 → 2022-06-30 | Standalone | Operating income |
| Ordinary income | −¥662m | 2023-01-01 → 2023-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥661m | 2023-01-01 → 2023-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Income before income taxes |
| Net income | −¥664m | 2023-01-01 → 2023-06-30 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥771m | 2022-01-01 → 2022-06-30 | Standalone | Profit loss |
| Total assets | ¥1.7bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥1.9bn | at 2022-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥541m | at 2023-06-30 | Standalone | Liabilities |
| Total liabilities | ¥425m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2022-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2023-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2022-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥595m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥660m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | ¥82,000 | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥113m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥341m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-13.7 | 2023-01-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9 | 2023-04-01 → 2023-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.17 | 2022-01-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.53 | 2022-04-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.2% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.3% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 48,503,800 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,057,600 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥266m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥602m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥209m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-06-30 | ¥359m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-06-30 | −¥393m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥239m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥691m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥540m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 444
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in accrued expenses ope cf | CurrentYTDDuration_NonConsolidatedMember | 1030000 | JPY |
| Increase decrease in contract liabilities ope cf | Prior1YTDDuration_NonConsolidatedMember | -4603000 | JPY |
| Increase decrease in contract liabilities ope cf | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Other net ope cf | Prior1YTDDuration_NonConsolidatedMember | -20517000 | JPY |
| Other net ope cf | CurrentYTDDuration_NonConsolidatedMember | 7910000 | JPY |
| Subtotal ope cf | Prior1YTDDuration_NonConsolidatedMember | -656355000 | JPY |
| Subtotal ope cf | CurrentYTDDuration_NonConsolidatedMember | -589373000 | JPY |
| Interest income received ope cf | Prior1YTDDuration_NonConsolidatedMember | 11000 | JPY |
| Interest income received ope cf | CurrentYTDDuration_NonConsolidatedMember | 8000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration_NonConsolidatedMember | -645000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration_NonConsolidatedMember | -910000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration_NonConsolidatedMember | -3240000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration_NonConsolidatedMember | -5010000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration_NonConsolidatedMember | 4000 | JPY |
| Income taxes refund ope cf | CurrentYTDDuration_NonConsolidatedMember | 3000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration_NonConsolidatedMember | -660225000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration_NonConsolidatedMember | -595281000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration_NonConsolidatedMember | 82000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration_NonConsolidatedMember | 82000 | JPY |
| Increase in short term loans payable fin cf | Prior1YTDDuration_NonConsolidatedMember | 18000000 | JPY |
| Increase in short term loans payable fin cf | CurrentYTDDuration_NonConsolidatedMember | 130800000 | JPY |
| Decrease in short term loans payable fin cf | Prior1YTDDuration_NonConsolidatedMember | -13000000 | JPY |
| Decrease in short term loans payable fin cf | CurrentYTDDuration_NonConsolidatedMember | -16500000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration_NonConsolidatedMember | 336172000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Payments for issuance of common stock fin cf | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Payments for issuance of common stock fin cf | CurrentYTDDuration_NonConsolidatedMember | -940000 | JPY |
| Other net fin cf | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Other net fin cf | CurrentYTDDuration_NonConsolidatedMember | -0 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration_NonConsolidatedMember | 341172000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration_NonConsolidatedMember | 113359000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration_NonConsolidatedMember | -319052000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration_NonConsolidatedMember | -481839000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 1790988000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 1727270000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant_NonConsolidatedMember | 1471935000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant_NonConsolidatedMember | 1245431000 | JPY |
| Raw materials | Prior1YearInstant_NonConsolidatedMember | 70327000 | JPY |
| Raw materials | CurrentQuarterInstant_NonConsolidatedMember | 58148000 | JPY |
| Work in process | Prior1YearInstant_NonConsolidatedMember | 1151000 | JPY |
| Work in process | CurrentQuarterInstant_NonConsolidatedMember | 1590000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 278211000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 278211000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember | 278211000 | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |